{"url_path":"/sec/curx/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2025942/0001493152-26-022898-index.html","accession_number":"0001493152-26-022898","cik":"0002025942","ticker":"CURX","issuer_name":"Curanex Pharmaceuticals Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/2025942/0001493152-26-022898-index.html","primary_entity_key":"0002025942","primary_entity_name":"Curanex Pharmaceuticals Inc"},"word_count":85,"has_tables":true,"body_markdown":"**Item\n9.01. Financial Statements and Exhibits.**\n\n** **\n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n99.1\n \n[Press Release of Curanex Pharmaceuticals Inc dated May 14, 2026](ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its\nbehalf by the undersigned hereunto duly authorized.\n\n \n\n \nCuranex\nPharmaceuticals Inc\n\n \n \n \n\nDate:\nMay 14, 2026\nBy:\n*/s/\nJun Liu*\n\n \nName:\nJun\nLiu\n\n \nTitle:\nChief\nExecutive Officer"}